Molteni Alfredo, Riva Marta, Borin Lorenza, Bernardi Massimo, Pelizzari Anna Maria, Freyrie Alessandra, Della Porta Matteo, Nichelatti Michele, Ravano Emanuele, Quaresmini Giulia, Mariotti Jacopo, Caramazza Domenica, Ubezio Marta, Guarco Simona, Gigli Federica, Greco Rosa, Cairoli Roberto, Morra Enrica
Hematology, AO Niguarda Ca' Granda, Milan, Italy.
Hematology, AO Niguarda Ca' Granda, Milan, Italy.
Leuk Res. 2016 Mar;42:21-7. doi: 10.1016/j.leukres.2016.01.006. Epub 2016 Jan 18.
5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
5-氮杂胞苷是高危骨髓增生异常综合征（MDS）和少粒细胞性急性髓系白血病（AML）的有效治疗方法。这项“真实世界”分析是对伦巴第地区一个名为REL（“Rete Ematologica Lombarda”）网络中10个中心接受5-氮杂胞苷治疗的185例患者进行的。目的是评估疾病和合并症风险评估对生存的影响。结果证实，无论年龄多大和是否存在合并症，5-氮杂胞苷在延长总生存期方面都有用。结果还鼓励早期治疗，因为国际预后评分系统（IPSS）-修订版高危MDS患者比极高危患者有更好的预后。根据IPSS细胞遗传学风险，中危和高危患者的预后没有差异。然而，根据IPSS-修订版细胞遗传学分层，较差的细胞遗传学风险对预后有负面影响。
